Work

A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.6631

Authors: E. Feldman, F. Giles, G. Roboz, K. Yee, T. Curcio, V. M. Rivera, M. Albitar, R. Laliberte, C. L. Bedrosian

Institutions: The University of Texas MD Anderson Cancer Center, Weill Cornell Medicine, ARIAD Pharmaceuticals (United States), Quest Diagnostics (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2336409148

Cites:

Cited by: 26

Related to: 10